Table 3.
Kaplan–Meier Cumulative Proportion of Surviving without Death from Metastasis according to 8th Edition AJCC Clinical cT Subcategory in 1841 Patients with Advanced Retinoblastoma
| Kaplan–Meier Estimate, % (95% CI) |
|||
|---|---|---|---|
| Variable | 1 yr | 5 yrs | 10 yrs |
| cT2a (n = 196) | 99 (98–100) | 98 (97–99) | 98 (97–99) |
| cT2b (n = 814) | 98 (97–99) | 96 (95–97) | 96 (95–97) |
| cT3a (n = 22) | 94 (89–99) | 88 (80–96) | 88 (80–96) |
| cT3b (n = 166) | 95 (93–97) | 95 (93–97) | 95 (93–97) |
| cT3c (n = 389) | 94 (89–99) | 92 (90–94) | 92 (90–94) |
| cT3d (n = 203) | 85 (82–88) | 84 (81–87) | 84 (81–87) |
| cT3e (n = 51) | 78 (72–84) | 75 (68–82) | 75 (68–82) |
| Pairwise Comparisons [Log-Rank Test] | ||||||
|---|---|---|---|---|---|---|
|
| ||||||
| cT2b | cT3a | cT3b | cT3c | cT3d | cT3e | |
| cT2a | 0.27 | 0.008 | 0.047 | 0.007 | <0.001* | <0.001* |
| cT2b | 0.065 | 0.19 | 0.002* | <0.001* | <0.001* | |
| cT3a | 0.46 | 0.62 | 0.46 | 0.14 | ||
| cT3b | 0.53 | 0.004 | <0.001* | |||
| cT3c | 0.001* | <0.001* | ||||
| cT3d | 0.127 | |||||
| Kaplan–Meier Cumulative Proportion of Surviving without Death from Metastasis according to Treatment Modality and Tumor Laterality† in 1841 Patients with Advanced Retinoblastoma | ||||
|---|---|---|---|---|
|
| ||||
|
Kaplan–Meier Point Estimates (95% CI), %
|
||||
| Variable | 1 yr | 5 yrs | 10 yrs | |
| Primary enucleation (n = 1128) | 96 (95–97) | 96 (95–97) | 96 (95–97) | |
| • Unilateral (n = 870) | 97 (96–98) | 96 (95–97) | 96 (95–97) | |
| • Bilateral (n = 258) | 95 (94–96) | 94 (92–96) | 94 (92–96) | |
| Systemic chemotherapy | Secondary enucleation (n = 315) | 93 (91–95) | 89 (87–91) | 89 (87–91) |
| • Unilateral (n = 161) | 89 (86–92) | 86 (83–89) | 86 (83–89) | |
| • Bilateral (n = 154) | 97 (96–98) | 93 (91–95) | 93 (91–95) | |
| Eye salvage (n = 398) | 94 (93–95) | 90 (88–92) | 90 (88–92) | |
| • Unilateral (n = 180) | 94 (93–95) | 93 (91–95) | 93 (91–95) | |
| • Bilateral (n = 218) | 91 (89–93) | 88 (85–91) | 88 (85–91) | |
| Pairwise Comparisons [Log-Rank] | ||
|---|---|---|
|
| ||
| Systemic Chemotherapy followed by Secondary Enucleation | Systemic Chemotherapy and Eye Salvage | |
| Primary enucleation | <0.001* | <0.001* |
| Systemic chemotherapy followed by secondary enucleation | 0.951 | |
| Pairwise Comparisons [Log-Rank] | |||||
|---|---|---|---|---|---|
|
| |||||
| Primary Enucleation Bilateral | Systemic Chemotherapy and Secondary Enucleation Unilateral | Systemic Chemotherapy and Secondary Enucleation Bilateral | Systemic Chemotherapy and Eye Salvage Unilateral | Systemic Chemotherapy and Eye Salvage Bilateral | |
| Primary enucleation unilateral | 0.210 | <0.001* | 0.327 | 0.070 | <0.001* |
| Primary enucleation bilateral | 0.007 | 0.905 | 0.477 | 0.049 | |
| Systemic chemotherapy and secondary enucleation unilateral | 0.015 | 0.094 | 0.453 | ||
| Systemic chemotherapy and secondary enucleation bilateral | 0.488 | 0.084 | |||
| Systemic chemotherapy and eye salvage unilateral | 0.284 | ||||
Overall comparison, P < 0.001.
AJCC = American Joint Committee on Cancer; c = clinical; CI = confidence interval; T = tumor.
*
Significant after adjustment for multiple comparisons according to Bonferroni.
†
The treatment modality for worse eye in bilateral RB cases was attributed to the patient.